Keywords: capricorn, study, provides, evidence, beta, blocker, benefits
CAPRICORN study provides evidence of beta blocker benefits post-MI
Article | 22 March 2001
The results of the CAPRICORN (Carvedilol Post Infarction SurvivalControl in Left Ventricular Dysfunction) study, evaluating the effect of GlaxoSmithKline and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
